Wave Life Sciences WVE Debt-to-equity

Debt-to-equity at other companies

Eli LillyLLY

1.6×-0.6×

Sarepta Therapeutics, Inc.SRPT

0.1×0.0×

Ionis PharmaceuticalsIONS

0.6×-0.7×

Madrigal Pharmaceuticals, Inc.MDGL

0.7×+0.5×

ALN

Alnylam PharmaceuticalsALNY

0.2×-0.9×

Beam TherapeuticsBEAM

0.2×+0.1×

FAQ

What is Wave Life Sciences's debt-to-equity?

Wave Life Sciences (WVE) reported debt-to-equity of 0.1× in Q2 2026.

How has Wave Life Sciences's debt-to-equity changed year-over-year?

Wave Life Sciences's debt-to-equity decreased by 38.4% year-over-year, from 0.2× to 0.1×.

What is the long-term trend for Wave Life Sciences's debt-to-equity?

Over 4 years (2020 to 2025), Wave Life Sciences's debt-to-equity has grown at a -44.2% compound annual growth rate (CAGR), from 0.4× to 0×.

What does debt-to-equity mean?

Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.